Liquid formulations for treatment of diseases or conditions
Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; liquid formulations comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration in a subject.
1. A method for treating uveitis in a human subject, the method comprising
administering to the human subject by intravitreal injection a volume of a liquid formulation comprising an effective amount of rapamycin to treat uveitis in the human subject, wherein
the liquid formulation comprises about 2% (w/w) rapamycin, about 94% (w/w) polyethylene glycol 400, and about 4% (w/w) ethanol,
the volume of the liquid formulation is about 20 μl, and
the administering is done once every two months.
2. A method of administering a liquid formulation, the method comprising:
administering to a human subject by intravitreal injection a volume of a liquid formulation comprising about 2% (w/w) rapamycin, about 94% (w/w) polyethylene glycol 400, and about 4% (w/w) ethanol, wherein
the human subject has uveitis,
the volume of liquid formulation is about 20 μl, and
the administering is done once every two months.